Message :
Required fields
TOKYO, July 29, 2021 /PRNewswire/ Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, Eisai ) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, Biogen ) today announced results of a longitudinal preliminary assessment of the clinical effects of lecanemab (development code: BAN2401) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) in June 2021 following 18 months of treatment in the open-label extension (OLE) of the Phase 2b proof-of-concept study in subjects with early Alzheimer s disease (AD) (Mild Cognitive Impairment [MCI] due to AD and mild AD) at the Alzheimer s Association International Conference (AAIC) held in Denver, Colo., United States and virtually from July 26 to 30, 2021 (Presentation No.: 57780).
KC woman diagnosed as pre-Alzheimer s weighs whether to get COVID-19 vaccine
Anne Fraser says she does not want to risk any brain loss Share Updated: 10:16 PM CDT Jul 29, 2021
Anne Fraser says she does not want to risk any brain loss Share Updated: 10:16 PM CDT Jul 29, 2021
Hide Transcript
Show Transcript CONFERENCE ARE ANNOUNCING WHAT THEY’VE FOUND SO FAR. RFO KANSAS CITY AND ANN FRASER. IT IS SOMETHING SHE’S WORRIED ABOUT HAVING A COMP. I DON ’ WANT TO DO ANYTHING THAT WOULD ALTER MY COURSE. ESH WAS DIAGNOSED AS PRE ALZHEIMER’S FIVE YEARS AGO. SHE HAS A FAMILY HISTORY OF IT AND IT’S YWH SHE HAS STAYED AWAY FOR NOW FROM GETTING THE COVID-19 VACCINE. IT’S NOT THAT SHE DOESN’T BELIEVE THE SCIENCE OR THAT SHE THINKS IT WON’T WKOR BUT GIVEN HERIA DGNOSIS. SHE DOESN’T WANT TO RISK ANY BRAIN LOSS WHATSOEVER. SO IF I WERE TO GET CODE THAT I MIGHT HAVE COGNITIVE DECLINE IF I GET THE GOT WILL I WILL I NOT I DON’T KNOW. SO I’M IT’S
By Reuters Staff
2 Min Read
FILE PHOTO: Marc Archambault, 70 of South Kingstown, Rhode Island,receives his first intravenous infusion of Aduhelm, Biogen s controversial recently approved drug for early Alzheimer s disease, at Butler Hospital, one of the clinical research sites in Providence, Rhode Island, U.S. June 16, 2021. Jessica Rinaldi/Pool via REUTERS.
(Reuters) - Biogen Inc and partner Eisai Co Ltd on Thursday revealed the design of an upcoming study of their controversial Alzheimer’s treatment, Aduhelm.
The study, designed to collect real-world, long-term effectiveness and safety data on Aduhelm, will enroll 6,000 patients over fours years in the United States, according to details released during the Alzheimer’s Association International Conference.
New insights into participation of underrepresented communities in Alzheimer’s clinical trials
A significant hurdle in developing therapeutics and care models for Alzheimer s disease that work for people of all ethnic and racial backgrounds is the recruitment and retention of traditionally underrepresented groups in clinical trials. At the Alzheimer s Association International Conference
® (AAIC
®) 2021, in Denver and virtually, researchers shared new evidence-based insights into why people from communities of color do and do not choose to participate in clinical trials.
Also at AAIC 2021, the National Institute on Aging (NIA), part of the U.S. National Institutes of Health, launched a new online tool, Outreach Pro, to help researchers and clinicians increase awareness and participation in clinical trials on Alzheimer s disease and other dementias, especially among traditionally underrepresented communities.
New study finds COVID-19 can cause changes in brain that mimic Alzheimer s disease
New study finds COVID-19 can cause changes in brain that mimic Alzheimer s disease
Stunning new research released Thursday on the long-term effects of COVID-19 on the brain shows the memory and attention issues caused by the disease that many people described as brain fog were actually caused by changes in the brain that mimic Alzheimer’s disease.
(FOX 9) - Stunning new research on the long-term effects of COVID-19 on the brain shows the memory and attention issues caused by the disease that many people described as brain fog were actually caused by changes in the brain that mimic Alzheimer’s disease.